Scholarlink

Background <p>Metabolic-associated fatty liver disease (MAFLD) and non-alcoholic fatty pancreatic disease (NAFPD) are increasingly recognized as components of metabolic syndrome, sharing common risk factors and pathogenic mechanisms. Understanding their association can enhance early detection and management strategies. Our study aims to assess the association between MAFLD and NAFPD.</p> Methods <p>This cross-sectional study included 72 adult cases with sonographically confirmed MAFLD. All participants underwent clinical evaluation, laboratory testing (including glycemic and lipid profiles, liver and pancreatic enzymes), and imaging studies (abdominal ultrasound and computed tomography (CT) pancreas protocol). Fatty Liver Index (FLI) and NAFLD Fibrosis Score (NFS) were calculated for all cases. Based on CT findings, cases were categorized into normal pancreas (<i>n</i> = 28) and fatty pancreas groups (<i>n</i> = 44).</p> Results <p>Patients with fatty pancreas were significantly older (54 ± 10 vs. 39 ± 12&#xa0;years, <i>p</i> &lt; 0.001), had higher body mass index (BMI) (33.4 ± 4.52 vs. 30.06 ± 5.18, <i>p</i> = 0.005), and more frequent diabetes (70.5% vs. 7.1%, <i>p</i> = 0.0001) and hypertension (47.7% vs. 10.7%, <i>p</i> = 0.001) than those with normal pancreas. They also had higher triglycerides (195.45 ± 86.99 vs. 140.07 ± 63.55, <i>p</i> = 0.005), lower high-density lipoprotein (HDL) (38.25 ± 12.19 vs. 44.96 ± 8.73, <i>p</i> = 0.014), higher FLI scores (78 ± 15.15 vs. 60.14 ± 24.32, <i>p</i> &lt; 0.001), and more advanced fibrosis (15.9% vs. 7.1%, <i>p</i> = 0.003).</p> Conclusions <p>NAFPD is associated with MAFLD and worsened metabolic and hepatic profiles. Their coexistence underscores the need for comprehensive metabolic assessment in affected cases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between metabolic associated fatty liver disease (MAFLD) and non-alcoholic fatty pancreatic disease (NAFPD) among Egyptian patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月25日

查看全文
  • Mohamed L. F. Abdelmeged,
  • Ahmed S. Allam,
  • Ahmed Elsayed Mohamed Kamal Elsayed,
  • Amal S. M. Bakir,
  • Samy M. A. Mahmoud

摘要

Background

Metabolic-associated fatty liver disease (MAFLD) and non-alcoholic fatty pancreatic disease (NAFPD) are increasingly recognized as components of metabolic syndrome, sharing common risk factors and pathogenic mechanisms. Understanding their association can enhance early detection and management strategies. Our study aims to assess the association between MAFLD and NAFPD.

Methods

This cross-sectional study included 72 adult cases with sonographically confirmed MAFLD. All participants underwent clinical evaluation, laboratory testing (including glycemic and lipid profiles, liver and pancreatic enzymes), and imaging studies (abdominal ultrasound and computed tomography (CT) pancreas protocol). Fatty Liver Index (FLI) and NAFLD Fibrosis Score (NFS) were calculated for all cases. Based on CT findings, cases were categorized into normal pancreas (n = 28) and fatty pancreas groups (n = 44).

Results

Patients with fatty pancreas were significantly older (54 ± 10 vs. 39 ± 12 years, p < 0.001), had higher body mass index (BMI) (33.4 ± 4.52 vs. 30.06 ± 5.18, p = 0.005), and more frequent diabetes (70.5% vs. 7.1%, p = 0.0001) and hypertension (47.7% vs. 10.7%, p = 0.001) than those with normal pancreas. They also had higher triglycerides (195.45 ± 86.99 vs. 140.07 ± 63.55, p = 0.005), lower high-density lipoprotein (HDL) (38.25 ± 12.19 vs. 44.96 ± 8.73, p = 0.014), higher FLI scores (78 ± 15.15 vs. 60.14 ± 24.32, p < 0.001), and more advanced fibrosis (15.9% vs. 7.1%, p = 0.003).

Conclusions

NAFPD is associated with MAFLD and worsened metabolic and hepatic profiles. Their coexistence underscores the need for comprehensive metabolic assessment in affected cases.